Bioxytran (BIXT) Total Current Liabilities (2010 - 2026)
Bioxytran (BIXT) posted Total Current Liabilities of $5.0 million for Q1 2026, up 54.16% sequentially from $3.2 million in Q4 2025, and up 76.16% YoY from $2.8 million in Q1 2025.
Bioxytran (BIXT) Total Current Liabilities (2010 - 2026) Analysis & Trends
Bioxytran has reported Total Current Liabilities for 17 years, with the latest figure at $5.0 million in Q1 2026.
- Quarterly Total Current Liabilities rose 76.16% year-over-year to $5.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.0 million (up 76.16% YoY) and the FY2025 annual result came in at $3.2 million, up 68.33% from the prior year.
- Total Current Liabilities improved to $5.0 million in Q1 2026 per BIXT's latest filing, from $3.2 million in the prior quarter.
- Over five years, Total Current Liabilities peaked at $5.3 million in Q2 2022 and troughed at $1.1 million in Q1 2024.
- A 5-year average of $3.1 million and a median of $3.0 million in 2022 frame the typical range for Total Current Liabilities.
- The sharpest annual moves came in 2024 and 2025: Total Current Liabilities tumbled 74.01% in 2024, then surged 154.87% in 2025.
- Over 5 years, Total Current Liabilities stood at $3.7 million in 2022, then retreated by 11.55% to $3.2 million in 2023, then tumbled by 40.49% to $1.9 million in 2024, then surged by 68.33% to $3.2 million in 2025, then soared by 54.16% to $5.0 million in 2026.
- According to Business Quant data, Total Current Liabilities over the past three periods registered $5.0 million, $3.2 million, and $3.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.90 Bn | 131.05 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 86.10 Bn | 78.11 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 65.56 Bn | 60.37 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 55.82 Bn | 50.68 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 42.14 Bn | 37.04 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 31.67 Bn | 28.36 Bn | 992.69 Mn | 1.51 Bn |
| 7 | BioNTech SE | 27.74 Bn | 9.35 Bn | 668.28 Mn | 2.49 Bn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | 438.74 Mn |
| 9 | Royalty Pharma | 27.38 Bn | 26.54 Bn | - | 630.93 Mn |
| 10 | Bioxytran | 2.52 Mn | 2.27 Mn | - | 5.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.01 Mn |
| Dec 31, 2025 | 3.25 Mn |
| Sep 30, 2025 | 3.06 Mn |
| Jun 30, 2025 | 2.78 Mn |
| Mar 31, 2025 | 2.84 Mn |
| Dec 31, 2024 | 1.93 Mn |
| Sep 30, 2024 | 1.24 Mn |
| Jun 30, 2024 | 1.23 Mn |
| Mar 31, 2024 | 1.12 Mn |
| Dec 31, 2023 | 3.24 Mn |
| Sep 30, 2023 | 2.33 Mn |
| Jun 30, 2023 | 2.77 Mn |
| Mar 31, 2023 | 4.29 Mn |
| Dec 31, 2022 | 3.67 Mn |
| Sep 30, 2022 | 3.00 Mn |
| Jun 30, 2022 | 5.33 Mn |
| Mar 31, 2022 | 4.89 Mn |
| Dec 31, 2021 | 3.28 Mn |
| Sep 30, 2021 | 2.68 Mn |
| Jun 30, 2021 | 2.21 Mn |